Literature DB >> 11741221

Comparison of the rates of deamidation, diketopiperazine formation and oxidation in recombinant human vascular endothelial growth factor and model peptides.

C Goolcharran1, J L Cleland, R Keck, A J Jones, R T Borchardt.   

Abstract

In this work, we examine the way in which stability information obtained from studies on small model peptides correlates with similar information acquired from a protein. The rates of deamidation, oxidation, and diketopiperazine reactions in model peptide systems were compared to those of recombinant human vascular endothelial growth factor (rhVEGF). The N-terminal residues of rhVEGF, a potent mitogen in angiogenesis, are susceptible to the aforementioned reactions. The degradation of the peptides L-Ala-L-Pro-L-Met (APM) and Gly-L-Gln-L-Asn-L-His-L-His (GQNHH), residues 1-3 and 8-12 of rhVEGF, respectively, and rhVEGF were examined at pH 5 and 8 at 37 degrees C. Capillary electrophoresis and high-performance liquid chromatography (HPLC) stability-indicating assays were developed to monitor the degradation of the penta- and tripeptides, respectively. The degradation of rhVEGF was determined by tryptic mapping and quantified by RP-HPLC. The rates of degradation of both peptides and the protein followed apparent first-order kinetics and increased with increasing pH. The tripeptide APM underwent diketopiperazine formation (Ala-Pro-diketopiperazine) and oxidation of the Met residue, whereas the pentapeptide GQNHH degraded via the deamidation pathway. The results indicate that the rates of deamidation and oxidation of the protein are comparable to those observed in the model peptides at both pH values. However, the rate of the diketo-piperazine reaction was slower in the protein than in the model peptide, which may be the result of differences in the cis-trans equilibrium of the X-Pro peptide bonds in the 2 molecules.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11741221      PMCID: PMC2751000          DOI: 10.1208/ps020105

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  19 in total

1.  Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site.

Authors:  Y A Muller; B Li; H W Christinger; J A Wells; B C Cunningham; A M de Vos
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

2.  The effects of a histidine residue on the C-terminal side of an asparaginyl residue on the rate of deamidation using model pentapeptides.

Authors:  C Goolcharran; L L Stauffer; J L Cleland; R T Borchardt
Journal:  J Pharm Sci       Date:  2000-06       Impact factor: 3.534

3.  Crystallization of the receptor binding domain of vascular endothelial growth factor.

Authors:  H W Christinger; Y A Muller; L T Berleau; B A Keyt; B C Cunningham; N Ferrara; A M de Vos
Journal:  Proteins       Date:  1996-11

Review 4.  Mechanism of enzymatic and nonenzymatic prolyl cis-trans isomerization.

Authors:  R L Stein
Journal:  Adv Protein Chem       Date:  1993

5.  Kinetics of diketopiperazine formation using model peptides.

Authors:  C Goolcharran; R T Borchardt
Journal:  J Pharm Sci       Date:  1998-03       Impact factor: 3.534

6.  Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations.

Authors:  A J Pötgens; N H Lubsen; M C van Altena; R Vermeulen; A Bakker; J G Schoenmakers; D J Ruiter; R M de Waal
Journal:  J Biol Chem       Date:  1994-12-30       Impact factor: 5.157

7.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

Authors:  K A Houck; N Ferrara; J Winer; G Cachianes; B Li; D W Leung
Journal:  Mol Endocrinol       Date:  1991-12

8.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms.

Authors:  K A Houck; D W Leung; A M Rowland; J Winer; N Ferrara
Journal:  J Biol Chem       Date:  1992-12-25       Impact factor: 5.157

9.  The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.

Authors:  B A Keyt; L T Berleau; H V Nguyen; H Chen; H Heinsohn; R Vandlen; N Ferrara
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

10.  VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells.

Authors:  T Cohen; H Gitay-Goren; R Sharon; M Shibuya; R Halaban; B Z Levi; G Neufeld
Journal:  J Biol Chem       Date:  1995-05-12       Impact factor: 5.157

View more
  3 in total

1.  Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis.

Authors:  Weiqiang Cheng; Elena Curti; Wanderson C Rezende; Clifford Kwityn; Bin Zhan; Portia Gillespie; Jordan Plieskatt; Sangeeta B Joshi; David B Volkin; Peter J Hotez; C Russell Middaugh; Maria Elena Bottazzi
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

Review 2.  The role of thiols and disulfides on protein stability.

Authors:  Maulik V Trivedi; Jennifer S Laurence; Teruna J Siahaan
Journal:  Curr Protein Pept Sci       Date:  2009-12       Impact factor: 3.272

3.  Osmotic-driven release kinetics of bioactive therapeutic proteins from a biodegradable elastomer are linear, constant, similar, and adjustable.

Authors:  Frank Gu; Ronald Neufeld; Brian Amsden
Journal:  Pharm Res       Date:  2006-03-24       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.